EGFR and lung carcinoma: EMT and/or CSC have been reported to confer drug resistance characteristics against a number of conventional therapeutics like taxol, vincristine, oxaliplatin, gemcitabine, cisplatin and 5-fluorouracil in human pancreatic cell lines, and against EGFR-targeted therapies erlotinib, cetuximab and gefitinib in lung cancer (Fuchs et al., 2008; Sabbah et al., 2008; Arumugam et al., 2009).